Related Experiment Videos

Once-a-day calcium antagonist for antianginal and antihypertensive therapy

¹Department of Research, University Hospital, Kantonsspital, Basel, Switzerland.

Journal of Cardiovascular Pharmacology

|January 1, 1988

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967).

Membrane & cell biology·2000

Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension·1998

Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique.

The Biochemical journal·1996

Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition.

Cardiovascular drugs and therapy·1996

Low- and high-density lipoproteins as mitogenic factors for vascular smooth muscle cells: individual, additive and synergistic effects.

Journal of vascular research·1995

Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.

Arteriosclerosis, thrombosis, and vascular biology·1995

See all related articles